Secondary Efficacy Endpoints Frequency/extent of myonecrosis post-PCI Assessed with serial CK-MB, cTnI/T Total duration of ischemia post-PCI Continuous ST-segment monitoring for 24 hours Criterion: 1mm of ST-deviation for at least one minute Composite of death/MI or Holter ischemia within 48 hours

Other Efficacy Endpoints Inflammatory response post-PCI: Peak rise* in sCD40L Peak rise* hsCRP Thrombin generation post-PCI Peak rise* in F 1.2 * Peak rise is defined as the rise in the biomarker from baseline to its peak value by 24 hours (-6 / +12 hours) post-PCI based on Core Laboratory analysis.

Primary Safety Endpoint TIMI Major Hemorrhage Adjudicated by CEC Either of the following: (1) Intracranial or (2) Hemorrhage (including via imaging study) that is associated with a fall in hemoglobin of >5 g/dL (or, when hemoglobin is not available, a fall in hematocrit of >15%) Transfusion adjusted for (1 unit = 1g/dl)

Baseline Characteristics EPT BIV P-value n = 573 n = 284 Age (yrs) 60.0 ± 11.1 59.7 ± 9.8 NS Male (%) 66 68 NS Prior MI (%) 22 20 Prior PCI (%) 25 24 Prior CABG (%) 7 Prior CHF (%) 5 6 Hypertension (%) 65 Cigarette Smoker (%) 38 36 Diabetes (%) 44 0.026 Dyslipidemia (%) 54 56 Mike, Since we present data from all 3 arms, shouldn’t we present the demographics from all three groups rather than just the two? I enlarged title font

Presenting Characteristics EPT BIV P-value n = 573 n = 284 ST Depression 30.8 27.5 Elevated Troponin I (%) 52.4 54.8 Elevated Troponin I > 10X ULN (%) 30.2 26.2 Elevated CK-MB (%) 20.1 18.3 Pre-PCI TMPG 0/1/2 Pre-PCI TMPG 3 NS NS NS NS 43.8 44.2 NS 56.2 55.8 NS

Primary Endpoint: Coronary Flow Reserve CFR Post Adenosine CTFC p = 0.036 open arteries p = 0.13 all pts p=NS Coronary Flow Reserve Corrected TIMI Frame Count N=516 N=238 N=501 N=232

Change in TIMI Frame Count After PCI vs After Adenosine Eptifibatide Bivalirudin p - value Pre-PCI CTFC 32 30.6 NS Post-PCI CTFC 19 21 0.16 Favors Eptifibatide Improvement in CTFC following PCI (Post PCI – Pre PCI, or delta in CTFC from pre to post PCI) 10 8 0.10 Post-Adeno CTFC 14 Improvement in CTFC following Adenosine (Post adenosine – Post PCI) 4.7 6 0.12 Favors Bival CFR Based Upon Improvement in CTFC After Adenosine (Post-PCI CTFC ÷ Post-Adeno CTFC) 1.33 1.43 0.036 P-value After Pre-Specified Adjustment for Abrupt Closure and Thrombotic Bail Out 0.13 Values expressed as a median.

Eptifibatide Bivalirudin 45 MPH 42 MPH (Post PCI) Speeds up by a factor of 1.33 Speeds up by a factor of 1.43 (Adenosine) (Post Adenosine) 60 MPH 60 MPH

TIMI Myocardial Perfusion Grade 3 Post-PCI O.R. 1.44 (95% CI 1.003-2.06) p = 0.048 pre-specified adjustment for baseline TMPG Post-PCI TMPG 3 N=506 N=232

Duration of Ischemia on Holter Monitoring through 24 Hours Post-PCI Ischemic Event by 24 hours Duration of Ischemia in Patients with an Event p=NS p=0.013 % Median Duration (minutes) N=525 N=265 N=28 N=15

Death, MI or Ischemia on Holter Monitoring through 48 Hours O.R. 1.38 (95% CI 0.93-2.06) for Death/MI/Ischemia (p=0.11) O.R. 1.45 (95% CI 0.85-2.46) for Death/MI (6.3% vs 8.8%) 18.0% 13.8% Ischemia 11.6% % Ischemia 8.7% D / MI 8.8% D / MI 6.3% MI 8.5% MI 6.3% Death 0% Death 0.4% N=530 N=267

Peak Rise in Troponin I Post-PCI Median troponin I (ng/ml) N=498 N=255

TIMI Major & Minor Hemorrhage within 48 Hours TIMI Major Hemorrhage p=0.308 EPT + ENOX vs BIV: p = 0.053 % TIMI Minor Hemorrhage EPT + ENOX vs BIV: p=0.201 EPT + UFH vs BIV: p=0.021 p=0.027 %

Transfusions within 48 Hours p<0.001 EPT + ENOX vs BIV: p = 0.001 EPT + UFH vs BIV: p = 0.003 %

PROTECT Trial: Summary The primary endpoint, the improvement in flow after adenosine or coronary flow reserve, was significantly greater for bivalirudin in open arteries, but when abrupt closure/bail out was adjusted for as pre-specified, the strategies were similar Final post adenosine CTFC (flow) was identical in the two arms Post-PCI myocardial perfusion was significantly improved by Eptifibatide Ischemia duration on the post-PCI Holter was significantly shorter with Eptifibatide Death / MI trended to be lower for Eptifibatide Peak rise in Tn trended to be lower for Eptifibatide The primary safety endpoint, TIMI major bleeding did not differ between strategies, TIMI minor bleeding and transfusion was significantly less with bivalirudin

PROTECT Trial: Conclusions Compared with Bivalirudin, Eptifibatide significantly improved myocardial perfusion and significantly reduced the duration of post-PCI ischemia; it also directionally reduced clinical events and myonecrosis, but these benefits came at the expense of an increase in non-fatal bleeding

Myocardial Infarction - Major Bleeding: Net Clinical Benefit Favors Bivalirudin Favors GP IIbIIIa / Eptifibatide 0.3 0.8 ∆ Major Bleeding ∆ MI REPLACE 2: 0.5 Net Benefit 0.7 2.2 ∆ Major Bleeding ∆ MI PROTECT: 1.5 40% DM, > 50% Tn+ Net Benefit Event Rate (%)